Beigene Ltd BGNE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:14 PM EDT
164.42quote price arrow up+2.17 (+1.34%)
Volume
77,562
52 week range
126.97 - 256.45
Loading...
  • Open164.51
  • Day High165.00
  • Day Low162.91
  • Prev Close162.25
  • 52 Week High256.45
  • 52 Week High Date05/08/23
  • 52 Week Low126.97
  • 52 Week Low Date04/19/24

Key Stats

  • Market Cap17.18B
  • Shares Out104.49M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta0.62
  • YTD % Change-8.8

KEY STATS

  • Open164.51
  • Day High165.00
  • Day Low162.91
  • Prev Close162.25
  • 52 Week High256.45
  • 52 Week High Date05/08/23
  • 52 Week Low126.97
  • 52 Week Low Date04/19/24
  • Market Cap17.18B
  • Shares Out104.49M
  • 10 Day Average Volume0.22M
  • Dividend-
  • Dividend Yield-
  • Beta0.62
  • YTD % Change-8.8

RATIOS/PROFITABILITY

  • EPS (TTM)-8.51
  • P/E (TTM)-19.33
  • Fwd P/E (NTM)-19.02
  • EBITDA (TTM)-1.12B
  • ROE (TTM)-22.26%
  • Revenue (TTM)2.459B
  • Gross Margin (TTM)73.40%
  • Net Margin (TTM)-35.86%
  • Debt To Equity (MRQ)25.05%

EVENTS

  • Earnings Date05/08/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beigene Ltd

 

Profile

MORE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small...
John Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer, General Manager - China
Julia Wang
Chief Financial Officer
Address
94 Solaris Avenue,, Camana Bay
Grand Cayman, BEJ
KY1-1108
Cayman Islands